Global Hypercholesterolemia Drugs Market 2016-2020

About Hypercholesterolemia

Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C. LDL carries cholesterol to the body and HDL removes cholesterol from the cells by reversing cholesterol transport to the liver.

Technavio’s analysts forecast the global hypercholesterolemia drugs market to decline at a CAGR of 6.78% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypercholesterolemia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generics, and off-label drugs used to treat hypercholesterolemia.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hypercholesterolemia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
Other prominent vendors
  • Alnylam Pharmaceuticals
  • Amarin
  • Amgen
  • AtheroNova
  • Aurobindo Pharma
  • Biocon
  • Biospherics
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis Therapeutics
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Concord Biotech
  • CymaBay Therapeutics
  • Daewoong Pharmaceutical
  • Daiichi Sankyo
  • Eli Lilly
  • Esperion Therapeutics
  • GlaxoSmithKline
  • HanAll BioPharma
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Kowa Company
  • Laboratoires
  • Livzon Pharmaceutical
  • Lupin Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Merz Pharmaceuticals
  • Mylan
  • Novartis
  • Regeneron Pharmaceuticals
  • ReGenX Biosciences
  • Santaris Pharma
  • Serometrix
  • Sun Pharmaceutical
  • Arbutus Biopharma
  • Teva Pharmaceuticals
  • Torrent Pharmaceuticals
  • Zydus Cadila
Market driver
  • Rising prevalence of chronic diseases
  • For a full, detailed list, view our report
Market challenge
  • Loss of patent exclusivity of branded therapies
  • For a full, detailed list, view our report
Market trend
  • Expected entry of cost-effective OTC versions
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hypercholesterolemia Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global hypercholesterolemia drugs market: AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, and Zydus Cadila.

Commenting on the report, an analyst from Technavio’s team said: “One of the major trends for market growth will be the increased use of combination therapies. Combinations of drugs are often used to treat conditions and they are mostly useful in managing lipid abnormalities. Combination therapies have advantages over monotherapies in terms of efficacy and a reduced incidence of adverse effects. Further, combination therapies have lesser manufacturing costs compared to the costs of manufacturing monotherapies administered concurrently, simpler logistics of distribution, and improved patient compliance by reducing the pill burden. Combination therapy in fixed dose combinations containing a statin and another lipid-lowering drug is available in the market.”

According to the report, one of the key drivers for market growth will be rising prevalence of chronic diseases. Chronic conditions such as obesity and diabetes are linked to lipid abnormalities and are a result of health risk behaviors. For instance, the prevalence of obesity has doubled between 1980 and 2014. In 2014, over 1.9 billion individuals were found to be overweight. Of these, over 600 million were obese. In the same year, the global prevalence of diabetes in individuals over 18 years of age was estimated to be 9%. According to a WHO report published in 2014, the global prevalence of diabetes was 8% in 2011 and is expected to rise to 10% by 2030. Regular use of anti-hypercholesterolemia drugs is necessary to lower cholesterol levels and reduce the risk of CVDs.

Further, the report states that stringent regulatory guidelines will be one of the major challenges for the market. The drug approval process across the globe is a stringent process demanding evidence from clinical trial studies. The regulatory authorities carefully study and evaluate the drug related data before approving it for use. The regulatory bodies examine some major factors such as safety, efficacy, carcinogenicity, mitogenicity, pharmacological data, pharmacodynamics effects, and drug interactions. Thus, a drug failing in any of these criteria is likely to receive a complete response letter (CRL) or be rejected by the regulatory agencies. On receiving a CRL, the drug applicant is required to furnish additional data pertaining to the drug. This, in turn, might require additional clinical trials and might increase the R&D expenditure for the drug.

Companies Mentioned

AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, Zydus Cadila.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
    • Drug profiles
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Different class of lipoproteins
    • Clinical application
    • Treatment guidelines
      • Table Evaluation of lipoprotein levels based on ATP III classification
    • Key buying criteria
      • Table Key buying criteria for hypercholesterolemia drugs
  • Hypercholesterol emia: An overview
    • History of hypercholesterolemia
      • Table Timeline of cholesterol lowering drugs
    • Hypercholesterolemia management market dynamics
      • Table Market dynamics for hypercholesterolemia
    • Hypercholesterolemia prescription landscape
      • Table Prescription landscape for statins 2015
      • Table Prescription landscape for ezetimibe 2015
      • Table Prescription landscape for other classes 2015
      • Table Distribution of cholesterol-lowering medication for individuals above 40 years
      • Table Percentage use of prescription cholesterol-lowering medication in US for various indications 2015
    • Management of hypercholesterolemia
      • Table Treatment of hypercholesterolemia
      • Table Pharmacological treatment of hypercholesterolemia
    • Epidemiology
      • Table High cholesterol levels by race and ethnicity in US 2015
    • Unmet medical needs and role of PCSK9 and CETP inhibitors
      • Table PCSK9 inhibitors in preclinical and clinical development 2015
  • Pipeline portfolio
    • Table Pipeline portfolio: Global hypercholesterolemia drugs market
    • Information on pipeline candidates
      • Table Pipeline share of hypercholesterolemia drugs
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global hypercholesterolemia drugs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Segmentation by type of disease
    • Table Classification of hyperlipidemia
    • FH
    • Non-FH
  • Market segmentation by MOA
    • Table Global hypercholesterolemia market segmentation by MOA
    • HMG-CoA reductase inhibitors
    • Fibric acid derivatives
    • Nicotinic acid
    • Bile acid sequestrants
    • Other
      • Table Global hypercholesterolemia market segmentation by MoA 2015
  • Market segmentation by drug class
    • Table Global hypercholesterolemia drugs market segmentation by drug class
    • Table Global hypercholesterolemia drugs market by drug class 2015 (% share)
    • Table Hypercholesterolemia drugs market revenue by drug class 2015-2020 ($ billions)
    • Statins
      • Table Global statin market 2015-2020 ($ billions)
      • Table Number of prescriptions for statins in US
      • Table Usage of statins for hypercholesterolemia in US 2015
      • Table Usage of statins for hypercholesterolemia in UK 2015
    • Non-statins
      • Table Global non-statins market 2015-2020 ($ billions)
      • Table Number of prescriptions for non-statins in US
      • Table Global hypercholesterolemia drugs market: YoY growth and revenue based on drug class 2015-2020
  • Geographical segmentation
    • Global hypercholesterolemia drugs market by geographical segmentation 2015-2020
      • Table Segmentation of global hypercholesterolemia drugs markets by geography 2015
      • Table Hypercholesterolemia drugs market revenue by geography 2015-2020 ($ billions)
      • Table Percentage share of hypercholesterolemia drugs market by geography 2015-2020 (%)
    • Hypercholesterolemia drugs market in Americas
      • Table Hypercholesterolemia drugs market in Americas 2015-2020 ($ billions)
      • Table Share of hypercholesterolemia drugs market in Americas by country 2015
    • Hypercholesterolemia drugs market in EMEA
      • Table Hypercholesterolemia drugs market in EMEA 2015-2020 ($ billions)
    • Hypercholesterolemia drugs market in APAC
      • Table Hypercholesterolemia drugs market in APAC 2015-2020 ($ billions)
      • Table Global hypercholesterolemia drugs market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Increasing risk of CVDs
    • Rising prevalence of chronic diseases
    • Promising pipeline of drugs
    • Change in ATP guidelines for management of hypercholesterolemia
    • Growing older population
      • Table Population aged 60 years and over: World, developed and developing regions ($ millions)
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Loss of patent exclusivity of branded therapies
    • Drawbacks associated with current therapies
    • High cost of therapy
    • Stringent regulatory guidelines
    • Lack of proper diagnosis
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Expected entry of cost-effective OTC versions
      • Table Arguments for and against OTC switch by pharmaceutical companies and regulatory organizations
    • Increasing use of statins
    • Increased use of combination therapies
    • Consideration of lifestyle management in ATP guidelines
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Market share analysis of global hypercholesterolemia drugs market 2015
      • Table Revenue from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: YoY revenue and growth rate of lipid franchise portfolio 2013-2015 ($ millions)
      • Table Key takeaways
    • Aegerion Pharmaceuticals
      • Table Aegerion: YoY revenue and growth rate of JUXTAPID 2013-2015 ($ millions)
      • Table Key takeaways
    • AstraZeneca
      • Table AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
      • Table AstraZeneca: Geographic segmentation of Crestor 2015 by revenue
      • Table Key takeaways
    • Merck
      • Table Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
      • Table Merck: Key takeaways
    • Pfizer
      • Table Pfizer: YoY revenue and growth rate of Lipitor 2013-2015 ($ billions)
      • Table Pfizer: Geographic segmentation of Lipitor by revenue 2015
      • Table Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
      • Table Key takeaways
    • Sanofi
      • Table Sanofi: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook